The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Other: Placebo
- Registration Number
- NCT06115603
- Lead Sponsor
- University of Arkansas, Fayetteville
- Brief Summary
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Cannabigerol Cannabigerol 1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant. Placebo Placebo 1mL of Placebo. Placebo is made in the form of MCT oil.
- Primary Outcome Measures
Name Time Method Digit Symbol Substitution Test (DSST) 75 minutes post CBG/placebo administration A paper-and-pencil task that measures attention/processing speed.
Rey Auditory Verbal Learning Test (AVLT) 75 minutes post CBG/placebo administration A paper-and-pencil/verbal test that measures verbal memory.
Iowa Gambling Task (IGT) 75 minutes post CBG/placebo administration A computerized task that measures decision making (an indicator of impulsivity/hyperactivity).
Sustained Attention to Response Task 75 minutes post CBG/placebo administration A computerized task that measures response inhibition.
Trail Making Test-Parts A and B (TMT-A&B) 75 minutes post CBG/placebo administration A paper-and-pencil task that measures
- Secondary Outcome Measures
Name Time Method Positive and Negative Affect Scale-Expanded Version Baseline, 45 minutes post CBG/placebo administration, 75 minutes post CBG/placebo administration Self-report measure of positive and negative affect. Scores range from 30-150 on each of the two types of affects, with higher scores representing greater affect.
Karolinska Sleepiness Scale Pre CBG/placebo administration, 75 minutes post CBG/placebo administration Self-report measure of subjective level of sleepiness at a particular time during the day. Scores range from 1-10, with higher scores representing greater sleepiness.
Brief Irritability Test Pre CBG/placebo administration, 75 minutes post CBG/placebo administration Self-report measure of irritability. Scores range from 5-30, with higher scores representing greater irritability.
Numeric Rating Scale (pain) Pre CBG/placebo administration, 75 minutes post CBG/placebo administration Self-report measure of subjective level of pain. Scores range from 0-10, with higher scores representing greater pain.
State-Trait Anxiety Inventory (State Version) Pre CBG/placebo administration, 75 minutes post CBG/placebo administration Self-report measure of state anxiety. Scores range from 20 to 80 with higher scores indicating greater anxiety.
Visual Analog Scales 75 minutes post CBG/placebo administration Self-report of state-like states (e.g., anxiety, hunger). This scale ranges from 0 to 100 with higher scores indicating higher levels of the indication.
Global Impression of Change 75 minutes post CBG/placebo administration Self-report measure of perceived change in ADHD symptoms. This scale ranges from 1 to 7 with higher scores indicating greater improvements.
Trial Locations
- Locations (1)
University of Arkansas
🇺🇸Fayetteville, Arkansas, United States